B A S E C A R E
Exclusive Interview by Hong Kong Economic Journal| Dr. Liang Bo Talks Freely about Assisted Production and Basecare Will Shape the Detection Industry
September 14, 2021 · Suzhou
HKEJ specially interviewed Dr. Liang Bo, chairman and general manager of Basecare, and talked in detail about Basecare's advantages in the market and how to cater to the market demand by improving the entire detection industry.

The article is reprinted from Hongkong Economic Journal
The mainland has implemented and promoted the three-child policy, and promoted supporting facilities, including the integration of marriage, fertility, parenting and employment rights and interests, which is beneficial to the assisted reproductive industry. As the industry leader, Basecare (02170) has long dominated the PGT market in China by obvious competitive advantages. With the optimization of the fertility policies and the increased penetration of the gene testing of assisted reproductive industry, Basecare is the most promising company under the new population pattern. HKEJ specially interviewed Dr. Liang Bo, chairman and general manager of Basecare, and talked in detail about Basecare's advantages in the market and how to cater to the market demand by improving the entire detection industry.

Basecare, listed in Hong Kong at the beginning of this year, is a leader in reproduction, the NGS segment market. It is dedicated to the R&D and clinical applications of high-throughput sequencing technology in reproductive health. As an innovative platform for China's gene testing solutions in assisted reproduction, Basecare’s main product, PGT-A kit, is the first PGD/PGS kit that is approved by the National Medical Products Administration and realizes commercialization in China. The kit is used to detect the abnormal number of embryo chromosomes prior to the transfer.


During the interview, Dr. Liang Bo pointed out that Basecare has many other advantages. “We focused on high-throughput sequencing in 2010 and completed the registration and certification of the first batch of gene sequencers in China. Therefore, in terms of the market, we started from the industrial registration and certification, that is, how to turn the technology into a product meeting clinical standards. The whole team considered how to meet clinical needs and national laws and regulations. Therefore, our advantage lies in the understanding of the product, including compliance with clinical requirements and national requirements, which is the first point. The second point is that the product technologies developed by us are relatively advanced in the industry. We are the first in China to receive the national-level innovation, which includes three requirements. First, the technology should be the first in China and internationally advanced. Second, it has great and clear clinical significance. Third, it can be industrialized on a large scale. Therefore, it can be said that Basecare is a technological leader.”

Perfect the assisted reproduction industry
The reason why Basecare has become the competitive leader in the NGS segment market is that Basecare is driven by the clinical-oriented R&D model, strong R&D capacity, and professional knowledge with successful experience. Dr. Liang Bo added, “Basecare does not only provide embryo detection, but also constructs a whole life cycle. From pre-marital check-up to pre-pregnancy examination, and from prenatal to postnatal and neonatal, we have complete kits and products that obtain the registration and certification, filling in the gaps in the market and clinical needs. Moreover, kits must be supported by instruments and equipment. Therefore, the biggest difference between Basecare and competitors is that some companies focus on services, some on technology, but we design our own instruments and equipment and build the entire automation system. What we hope is not only to test samples, but also to help all the assisted reproductive centers in the mainland to upgrade the entire testing procedure and provide them with a modern and complete solution. We will not be eager for quick success and instant profits, which is exactly the difference between us and our competitors.”

According to National Health Commission of the People’s Republic of China, the IVF pregnancy success rate was 46% and the abortion rate was about 20%. However, Basecare is able to increase the IVF pregnancy success rate to 72% and reduce the abortion rate to 6.9%, which is of great clinical significance and value. Dr. Liang Bo said, “At present, one in six couples in China is infertile, and there is about 300-billion-yuan to explore in the market of assisted reproduction. After the introduction of the three-child policy, relevant supporting policies will be introduced. Recently, there is a discussion on commercial insurance covering the PGD/PGS costs, or the policy of reward and support in many places. The whole market will definitely expand. Last year, the number of Chinese newborns was about 10.5 million, however, the number of test-tube babies was only 900,000, and the success rate was only 50%. That means only about 500,000 test-tube babies were born, the ratio of which was still relatively low. Therefore, in the future, Basecare will expand the production line to meet the huge market demand.”

Cooperate with QuantoBio to increase competitiveness

On August 4, Basecare signed a strategic cooperation agreement based on the application of flow cytometry (FCM) in andrology with Beijing QuantoBio Biotechnology Co. Ltd. The cooperation agreed that in the future, the two parties will integrate their technological advantages, jointly build the national largest regional innovation center for FCM research and development in Suzhou Industrial Park, and open up more innovative models for the application of FCM in andrology. Dr. Liang Bo pointed out, “QuantoBio has a development history of more than 40 years and is a leader in FCM. Currently. About 300 million men in China have infertility problems, who need sperm detection in the future. Therefore, we hope to build the largest FCM research center with QuantoBio, obtain the registration and certification according to the sperm characteristics and clinical application demands, fully automate the sperm detection and expand the whole product pipeline. Cooperation with QuantoBio is only a starting point and our ultimate goal is to build a brand-new industrial chain. We should not only take the lead in China, but also in the world. We hope to serve patients worldwide and reduce the cost to the lowest.”